10月5日 - ** 百时美施贵宝（BMY.N）盘前股价下跌1.9%，报60美元
** 利林克合伙公司（Leerink Partners）将这家制药公司的股票评级从“跑赢大盘”下调至“与大盘持平”，并将目标价从73美元下调至59美元
** 截至上一交易日收盘，BMY今年以来累计上涨13.4%；新目标价暗示股价仍有约3.5%的下行空间
** 该券商指出，BMY的三个关键项目存在不确定性，且即将面临专利到期
** 称实验性肺病药物阿米帕兰（admilparant）在疗效和安全性方面可能令人失望，包括可能引发的肝脏问题和低血压；将2032年销售额预期下调38%
** 质疑实验性抗凝血药milvexian能否在预防心律不齐患者中风方面与百时美施贵宝的Eliquis相媲美；将2032年销售额预期下调25%
** 指出，即使抗精神病药物Cobenfy获批用于治疗阿尔茨海默病相关精神病，价格更低的仿制抗精神病药物仍可能限制其需求
** 将2032年每股收益（EPS）预期下调11%至4.96美元
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.